You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

BYVALSON Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Byvalson, and when can generic versions of Byvalson launch?

Byvalson is a drug marketed by Abbvie and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in fifteen countries.

The generic ingredient in BYVALSON is nebivolol hydrochloride; valsartan. There are fourteen drug master file entries for this compound. Additional details are available on the nebivolol hydrochloride; valsartan profile page.

DrugPatentWatch® Generic Entry Outlook for Byvalson

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Paragraph IV (Patent) Challenges for BYVALSON
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
BYVALSON Tablets nebivolol hydrochloride; valsartan 5 mg/80 mg 206302 1 2017-06-09

US Patents and Regulatory Information for BYVALSON

BYVALSON is protected by two US patents.

Patents protecting BYVALSON

Compositions comprising nebivolol
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Compositions comprising nebivolol
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF TREATING HYPERTENSION

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie BYVALSON nebivolol hydrochloride; valsartan TABLET;ORAL 206302-001 Jun 3, 2016 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie BYVALSON nebivolol hydrochloride; valsartan TABLET;ORAL 206302-001 Jun 3, 2016 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for BYVALSON

When does loss-of-exclusivity occur for BYVALSON?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Patent: 15
Estimated Expiration: ⤷  Try a Trial

Patent: 96
Estimated Expiration: ⤷  Try a Trial

Australia

Patent: 05249514
Estimated Expiration: ⤷  Try a Trial

Patent: 05332300
Estimated Expiration: ⤷  Try a Trial

Austria

Patent: 09627
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 69881
Estimated Expiration: ⤷  Try a Trial

Patent: 10694
Estimated Expiration: ⤷  Try a Trial

China

Patent: 1022791
Estimated Expiration: ⤷  Try a Trial

Patent: 1242827
Estimated Expiration: ⤷  Try a Trial

Patent: 2188708
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 53418
Estimated Expiration: ⤷  Try a Trial

Patent: 90691
Estimated Expiration: ⤷  Try a Trial

Patent: 82711
Estimated Expiration: ⤷  Try a Trial

Patent: 74658
Estimated Expiration: ⤷  Try a Trial

Patent: 08015
Estimated Expiration: ⤷  Try a Trial

Hong Kong

Patent: 04570
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 9999
Estimated Expiration: ⤷  Try a Trial

Patent: 7552
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 08545742
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 1910
Estimated Expiration: ⤷  Try a Trial

Patent: 3759
Estimated Expiration: ⤷  Try a Trial

Russian Federation

Patent: 03037
Estimated Expiration: ⤷  Try a Trial

Patent: 41653
Estimated Expiration: ⤷  Try a Trial

Patent: 93335
Estimated Expiration: ⤷  Try a Trial

Patent: 06147220
Estimated Expiration: ⤷  Try a Trial

Patent: 07148414
Estimated Expiration: ⤷  Try a Trial

Patent: 10130950
Estimated Expiration: ⤷  Try a Trial

Singapore

Patent: 2255
Estimated Expiration: ⤷  Try a Trial

Patent: 2734
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 0610708
Estimated Expiration: ⤷  Try a Trial

Patent: 0710355
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 1236166
Estimated Expiration: ⤷  Try a Trial

Patent: 1310037
Estimated Expiration: ⤷  Try a Trial

Patent: 070044833
Estimated Expiration: ⤷  Try a Trial

Patent: 080025699
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BYVALSON around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2006130174 ⤷  Try a Trial
New Zealand 551910 Compositions comprising nebivolol and an angiotensin II receptor antagonist (ARB) ⤷  Try a Trial
China 101022791 Compositions comprising nebivolol ⤷  Try a Trial
Canada 2610694 COMPOSITIONS A BASE DE NEBIVOLOL (COMPOSITIONS COMRISING NEBIVOLOL) ⤷  Try a Trial
Israel 179999 תכשירים המכילים נביבולול ואנטגוניסט של קולטן אנגיוטנסין ii ושימושים שלהם (Compositions comprising nebivolol and an angiotensin ii receptor antagonist and uses thereof) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for BYVALSON

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0334429 SPC/GB96/048 United Kingdom ⤷  Try a Trial PRODUCT NAME: NEBIVOLOL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR HYDRATE; REGISTERED: NL RVG/19317 19951018; UK 00242/0309 19960509
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.